# Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients

> **NCT02414009** · PHASE2 · COMPLETED · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 82 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Temozolomide
- **DRUG:** Irinotecan
- **DRUG:** Fluorouracil
- **DRUG:** Leucovorin

## Key facts

- **NCT ID:** NCT02414009
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2019-07-30
- **Final completion:** 2019-07-30
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2021-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02414009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02414009, "Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02414009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*